Drug Profile
Research programme: anti-CD86 monoclonal antibodies - Aida Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aida Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action CD86 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in China (Parenteral)
- 13 Jun 2006 Preclinical trials in Autoimmune disorders in China (Parenteral)